Literature DB >> 9885385

Natural history of macular subretinal hemorrhage in age-related macular degeneration.

A Scupola1, G Coscas, G Soubrane, E Balestrazzi.   

Abstract

PURPOSE: To define the natural course of extensive submacular hemorrhage in age-related macular degeneration (AMD). PATIENTS AND METHODS: The clinical charts of 54 patients (60 eyes) older than 55 years with subretinal hemorrhage larger than 1 disk diameter and extending beneath the fovea were retrospectively reviewed. The age of the patient, the use of antihypertensive or anticoagulant medication, visual acuity, biomicroscopic and fluorescein and indocyanine green (in 33 cases) angiographic data were recorded at presentation and during follow-up.
RESULTS: At the initial examination, average visual acuity was 20/240 (range from 20/70 to light perception). During follow-up (mean 24 months) visual acuity worsened in 80% of the eyes with a mean final visual acuity of 20/1, 250 (range from 20/100 to light perception). The initial size and thickness of hemorrhage were correlated with initial and final visual acuity. Recurrence of hemorrhage resulted in an important impact on final visual acuity. Anatomic outcome showed fibrous tissue proliferation in 23 eyes (38.3%), atrophic scar in 15 eyes (25%) and occurrence of a retinal pigment epithelium tear in 13 eyes (21.6%).
CONCLUSION: The visual outcome in eyes with submacular hemorrhages due to AMD is very poor. Size and thickness of the hemorrhage influenced negatively the natural prognosis. A surgical approach can be considered although it has not yet a widespread use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9885385     DOI: 10.1159/000027400

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  59 in total

1.  Visual acuity and structural findings in old age-related macular degeneration.

Authors:  Aila Riusala; Seppo Sarna; Ilkka Immonen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-04-15       Impact factor: 3.117

Review 2.  [Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration].

Authors:  H T Agostini; S Bopp; N Feltgen
Journal:  Ophthalmologe       Date:  2017-05       Impact factor: 1.059

3.  Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Authors:  Jost Hillenkamp; Vladimir Surguch; Carsten Framme; Veit-Peter Gabel; Helmut G Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

4.  Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.

Authors:  J J González-López; G McGowan; E Chapman; D Yorston
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

5.  [Subretinal hemorrhage. Natural course and staging].

Authors:  S Bopp
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

6.  Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage.

Authors:  Y Oshima; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

7.  Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.

Authors:  Takeshi Mizutani; Tsutomu Yasukawa; Yuya Ito; Ayae Takase; Yoshio Hirano; Munenori Yoshida; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

8.  Efficacy and toxic effect associated with subretinal tissue plasminogen activator injection in treating submacular hemorrhage.

Authors:  Jia-Ning Ren; Jie Peng; Yu Xu; Qi Zhang; Shuang-Shuang Chen; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

9.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

10.  Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Authors:  Dimitrios A Karagiannis; Ioannis D Ladas; Efstratios Parikakis; Ilias Georgalas; Athanasios Kotsolis; Giorgos Amariotakis; Vasileios Soumplis; Panagiotis Mitropoulos
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.